AI 聊天
Loading data for ALPMY — first visit, this takes a few seconds.

Astellas Pharma Inc.

ALPMY · OTC Markets OTCPK · USD

15.05 -0.30 (-1.95%)

收盤價: Sep 23, 2026, 7:54 PM

市值
$26.98B
下次財報日期
Oct 29, 2026

Astellas Pharma Inc.(ALPMY)股價、分析與資料

您正在查看免費總覽

建立免費帳戶即可查看該標的的財務、選擇權、預測及全部內容。

內在價值

估值模型屬於 Pro 功能。登入或升級後可查看完整分析。

查看方案 →

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →

正在載入...

最新財報

已通報較預期YoY 變更
營收n/an/a
EPSn/an/a

下次財報

開盤前。

估計 · 升級 →

查看財報詳情 →

指標

買價
15
市值
27B
淨利(ttm)
365B
0.09
1.03
14.61
33.44
P/B (ttm)
2.19
P/S (ttm)
0.01
財報日期
Oct 29, 2026
賣價
15.11
成交量
10,964
20 日平均成交量
143,312
開盤價
15.25
前收盤價
15.35
當日區間
14.98 - 15.25
52 週範圍
10.03 - 17.35
股利
$0.50 (3.23%)
除息日
Mar 31, 2026

關於 Astellas Pharma Inc.

查看公司資料 →
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan. Drug Manufacturers - General · Healthcare

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

類股 Healthcare
IPO 日期 Dec 29, 2009
員工 14,099
證券交易所 OTC Markets OTCPK
股票代號 ALPMY